2021
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes A, Samad B, Tsui J, Chew N, Yan P, Reeder G, Kushnoor D, Shen A, Davidson B, Barczak A, Adkisson M, Edwards A, Naser M, Barry K, Courau T, Hammoudi T, Argüello R, Rao A, Olshen A, Consortium T, Spitzer M, Fong L, Nelson A, Kumar R, Lee J, Burra A, Hsu J, Hackett C, Tolentino K, Sjarif J, Johnson P, Shao E, Abrau D, Lupin L, Shaw C, Collins Z, Lea T, Corvera C, Nakakura E, Carnevale J, Alvarado M, Loo K, Chen L, Chow M, Grandis J, Ryan W, El-Sayed I, Jablons D, Woodard G, Meng M, Porten S, Okada H, Tempero M, Ko A, Kirkwood K, Vandenberg S, Guevarra D, Oropeza E, Cyr C, Glenn P, Bolen J, Morton A, Eckalbar W, Cai C, Zhan J, Davis K, Kelley R, Chapman J, Atreya C, Patel A, Daud A, Ha P, Diaz A, Kratz J, Collisson E, Fragiadakis G, Erle D, Boissonnas A, Asthana S, Chan V, Krummel M. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell 2021, 185: 184-203.e19. PMID: 34963056, PMCID: PMC8862608, DOI: 10.1016/j.cell.2021.12.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCensusesCluster AnalysisCohort StudiesComputational BiologyFlow CytometryGene Expression Regulation, NeoplasticHumansNeoplasmsRNA-SeqSan FranciscoTranscriptomeTumor MicroenvironmentUniversitiesConceptsTumor immune microenvironmentIndividual tumorsTumor gene expression patternsCancer immunityImmune microenvironmentImmune compositionImmune systemTumor biologyUnique immuneTissue of originFlow cytometryCancer typesDriver mutationsImmune organizationDominant patternStandardized protocolTumorsSignificant heterogeneityCancerUniversity of CaliforniaTissueGene expression patternsCommon patternTherapyImmuneImproved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgery
2016
Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget 2016, 5: 80415-80425. PMID: 27533453, PMCID: PMC5348330, DOI: 10.18632/oncotarget.11246.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAdenocarcinomaAdenocarcinoma of LungAnimalsAntigens, CDAntineoplastic AgentsCadherinsCell MovementEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLung NeoplasmsMaleMice, NudeMiddle AgedNeoplasm InvasivenessSignal TransductionSmoothened ReceptorTime FactorsTumor BurdenXenograft Model Antitumor AssaysZinc Finger Protein GLI1ConceptsEpithelial-mesenchymal transitionLung adenocarcinomaE-cadherin expressionTumor growthLung adenocarcinoma metastasisPotential therapeutic targetInhibition of GLICell migrationAdenocarcinoma metastasisLung cancerInvasion/metastasisTumor invasion/metastasisIndependent cohortGLI inhibitorsSmall molecule inhibitorsTherapeutic targetAdenocarcinomaHuman lungTherapeutic agentsMetastasisCell invasionWound healingCommon typeRole of GliMolecule inhibitors
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker